Anavex’s experimental drug fails Rett syndrome study, stock falls
Anavex Life Sciences, a biotech company that has come under fire for trying to spin its clinical trial results, wants to claim partial success on a late-stage trial in kids with Rett syndrome, a rare genetic neurological disorder. However, the biotech’s own ad-hoc analysis says otherwise.
Anavex said Tuesday that its study of a compound known as blarcamesine “showed improvement on the key co-primary endpoint Rett Syndrome Behaviour Questionnaire” (RSBQ), a 45-item questionnaire conducted by patient caregivers, but it failed to meet the other primary endpoint of Clinical Global Impression – Improvement (CGI-I), a 7-point score given by study investigators.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
